Open access
Oct 2026
Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first-line therapy
Background Treatment options for refractory gastric cancer are limited. Preclinical data suggest interplay between angiogenesis and immune regulation, with vascular endothelial growth factor impairing antitumor immunity through decreasing antigen presentation, effector function, and immune cell trafficking. This phase...
J. W. Lee, P. Oberstein, J. Goldberg et al.
· ESMO gastrointestinal oncolo... · 0 citations